Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Avrio Biopharmaceuticals (Avrio), a wholly-owned subsidiary of Irvine Pharmaceutical Services (Irvine), has received approval to manufacture and ship pharmaceutical products by the California Department of Public Health, Food and Drug Branch (Cal FDB).
Subscribe to our email newsletter
Avrio’s newly built, 20,000 square foot, aseptic fill-and-finish facility includes three aseptic suites and five production suites with each suite having its own dedicated air handling system.
In addition to a production area designed to provide clients flexibility and scalability, Avrio also includes laboratory space for quality control, microbiology, formulation and a pilot suite. Furthermore, Irvine, located just across the street, has over 65,000 square feet of laboratory space which provides complete cGMP analytical CMC support.
Avrio said that with multiple manufacturing contracts in place and a number of agreements underway, it has continued to value the core principles of its affiliate, Irvine Pharmaceutical Services.
Assad Kazeminy, founder and CEO of Irvine, said: “For the past 22 years we have been dedicated to continual improvement of our systems and infrastructures in order to better serve the needs of our clients. With the addition of Avrio, we can now support our clients from start to finish via a seamless partnership.”